Compare QDEL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | GERN |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2022 | N/A |
| Metric | QDEL | GERN |
|---|---|---|
| Price | $12.25 | $1.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.25 | $2.17 |
| AVG Volume (30 Days) | 2.6M | ★ 15.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | N/A |
| Revenue This Year | $3.51 | $26.91 |
| Revenue Next Year | $3.86 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.86 | $1.04 |
| 52 Week High | $37.24 | $2.01 |
| Indicator | QDEL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 48.64 |
| Support Level | $10.86 | $1.43 |
| Resistance Level | $17.78 | $1.72 |
| Average True Range (ATR) | 0.98 | 0.07 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 21.15 | 31.67 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.